C
Craig Devoe
Researcher at Hofstra University
Publications - 40
Citations - 4589
Craig Devoe is an academic researcher from Hofstra University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 13, co-authored 34 publications receiving 1200 citations. Previous affiliations of Craig Devoe include North Shore University Hospital & North Shore-LIJ Health System.
Papers
More filters
Journal ArticleDOI
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.
Rimda Wanchoo,Sabine Karam,Nupur N. Uppal,Valerie S. Barta,Gilbert Deray,Craig Devoe,Vincent Launay-Vacher,Kenar D. Jhaveri +7 more
TL;DR: Although initially thought to be rare, the incidence rates of renal toxicities might be higher as identified by recent studies, Steroids appear to be effective in treating the immune-related adverse effects noted with these agents.
Journal ArticleDOI
Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
Hervé Tiriac,Pascal Belleau,Dannielle D. Engle,Dennis Plenker,Astrid Deschênes,Tim D.D. Somerville,Fieke E. M. Froeling,Richard A. Burkhart,Robert E. Denroche,Gun-Ho Jang,Koji Miyabayashi,C. Megan Young,C. Megan Young,Hardik Patel,Michelle Ma,Joseph F. LaComb,Randze Lerie Palmaira,Ammar A. Javed,Jasmine Huynh,Molly E. Johnson,Kanika Arora,Nicolas Robine,Minita Shah,Rashesh Sanghvi,Austin Goetz,Cinthya Y. Lowder,Laura A. Martello,Else Driehuis,Nicolas Lecomte,Gokce Askan,Christine A. Iacobuzio-Donahue,Hans Clevers,Laura D. Wood,Ralph H. Hruban,Elizabeth D. Thompson,Andrew J. Aguirre,Brian M. Wolpin,Aaron R. Sasson,Joseph Kim,Maoxin Wu,Juan Carlos Bucobo,Peter J. Allen,Divyesh V. Sejpal,William Nealon,James Sullivan,Jordan M. Winter,Phyllis A. Gimotty,Jean L. Grem,Dominick J. DiMaio,Jonathan M. Buscaglia,Paul M. Grandgenett,Jonathan R. Brody,Michael A. Hollingsworth,Grainne M. O'Kane,Faiyaz Notta,Edward J. Kim,James M. Crawford,Craig Devoe,Allyson J. Ocean,Christopher L. Wolfgang,Kenneth H. Yu,Ellen Li,Christopher R. Vakoc,Benjamin Hubert,Sandra Fischer,Sandra Fischer,Julie M. Wilson,Richard A. Moffitt,Jennifer J. Knox,Alexander Krasnitz,Steven Gallinger,Steven Gallinger,Steven Gallinger,David A. Tuveson +73 more
TL;DR: A pancreatic cancer patient-derived organoid (PDO) library is generated that recapitulates the mutational spectrum and transcriptional subtypes of primary Pancreatic cancer and proposes that combined molecular and therapeutic profiling of PDOs may predict clinical response and enable prospective therapeutic selection.
Journal ArticleDOI
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
Sunil R. Hingorani,Sunil R. Hingorani,William P. Harris,J. Thaddeus Beck,Boris A. Berdov,Stephanie Ann Wagner,Eduard M. Pshevlotsky,Sergei Tjulandin,Oleg Gladkov,Randall F. Holcombe,Ronald L. Korn,Natarajan Raghunand,Samuel S. Dychter,Ping Jiang,H. Michael Shepard,Craig Devoe +15 more
TL;DR: PEGPH20 in combination with Gem was well tolerated and may have therapeutic benefit in patients with advanced PDA, especially in those with high HA tumors.
Journal ArticleDOI
Genomic Profiling of Small Bowel Adenocarcinoma
Alexa B. Schrock,Craig Devoe,Robert R. McWilliams,James Sun,Thomas Aparicio,Philip J. Stephens,Jeffrey S. Ross,Jeffrey S. Ross,Richard H. Wilson,Vincent A. Miller,Siraj M. Ali,Michael J. Overman +11 more
TL;DR: The first large-scale genomic comparison of SBA with colorectal cancer and gastric carcinoma is presented, establishing SBA as a molecularly unique intestinal cancer.
Journal ArticleDOI
Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer.
TL;DR: Although phase I-II studies showed promising results in patients with high hyaluronic acid expressing tumors, the phase III HALO 301 study failed to miss it’s primary endpoint and further development of PEHPH20 is halted, implying that targeting desmoplasia alone is not sufficient and other intrinsic factors may be at play.